| Dear Doc | Alzheimer’s Awareness Day |
| New Additions to the Easton Center | Clinical Trials |
Written By: Monica Moore
250,000 people in Los Angeles County suffer from Alzheimer’s disease or other forms of dementia, and in response to this, the Central Branch of the Los Angeles Public Library and the UCLA-Easton Center were called into action to help and to spread the word about this terrible disease - what is being done and what the community can do about it. Experts from the three local California Alzheimer’s Disease Centers (UCLA, USC, and USC Rancho Los Amigos) came together on Saturday, January 28, 2017, to discuss the latest in research and care surrounding Alzheimer's disease.
Sarah Kremen, MD and Edmond Teng, MD, PhD were on hand from the UCLA-Easton Center, and spoke about the basics of Alzheimer’s disease and recent research findings. John Ringman, MD, MS from USC presented “What is My Risk for Developing Alzheimer’s Disease: New Perspectives on Genetics” to explain the role genetics has on Alzheimer’s. Following the informative lectures, a panel of experts in the Alzheimer’s field took the stage to answer questions from the audience. The panel featured Drs. Sarah Kremen, Edmond Teng, and John Ringman, as well as Freddi Segal-Gidan, PA, PhD (Director, USC - Rancho Los Amigos Alzheimer’s Disease Center), Donna Benton (Director, Los Angeles Caregiver Resource Center), and Petra Niles, MSG (Alzheimer’s Greater LA). The panel expressed the importance of research and clinical care to help those currently with Alzheimer’s disease and those who are at risk for developing the disease in the future, as well as the importance of advocating for increased funding for research and care through the state and federal government.
The day was complimented by a beautiful brain healthy lunch provided by Silverado Beverly Place, and a resource fair filled with information from a wide variety of senior agencies in Los Angeles. It was a wonderful day, and we are so thankful to those who attended, Central Branch of the Los Angeles Public Library, and of course the experts who gave their time to the community on a Saturday!
New Additions to the Easton Center
Please join us in welcoming three new members to the Easton Center.
Photo: Lauren Garcia
Lauren joins the Mary S. Easton Center as the newest member of the Kagan Clinical Trials team. Lauren graduated from Santa Clara University with a B.S. in Biology and Minors in Bioengineering & Music. With a strong interest in Alzheimer's disease, Lauren started volunteering at the Center to learn more about the research that is going on. She is excited to officially be a part of UCLA and the Kagan Clinical Trials team as a Staff Research Associate!
Photo: Lina Lee
Lina has joined the Mary S. Easton Center as the newest member of the Cognitive Neuropsychology Lab. Her B.S. degree in Cognitive Neuroscience from UC San Diego has both interested and prepared her to step foot in the field of neurology and neuropsychology, and she is thrilled to join the lab to further explore the wonders of brain-behavior relationships. She comes to UCLA with a background of contribution to various research labs, ranging from interventional rehabilitative studies with incarcerated veterans who suffer from post-traumatic stress disorder and acquired brain injuries, to observational studies in the pediatric population with neurodevelopmental disorders. As she works toward her pursuit of a Ph.D. degree in clinical psychology, Lina looks forward to welcoming the opportunities and challenges to come at the Easton Center!
Photo: Michelle Torreliza
Michelle completed her associate degree in Medical Assisting in 2000 from Pasadena City College. She has been working as a Clinical Research Coordinator for the past 16 years in various indications such as, Ophthalmology, Musculoskeletal, Endocrinology, Gastroenterology, and Reproductive health. One of the reasons why Michelle enjoys being a coordinator is that she finds fulfillment in helping patients and getting to know them. She is eager to learn another indication in clinical trials, Alzheimer's disease, especially since her grandmother suffered from the disease. Michelle is very excited to be a part of the Kagan Clinical Trials team, and to learn more about Alzheimer’s disease as well as what kinds of research are being done to help individuals who suffer from the progressive disease.
Clinical Research Opportunities
If you would like to advance Alzheimer's disease research, please consider participating at the Easton Center. Below are the current recruiting trials. For a complete list of enrolling studies, visit our website at www.eastonad.ucla.edu.
The ENGAGE study is a Phase III clinical trial sponsored by Biogen of the investigational drug aducadumab. Individuals aged 50-85 who are diagnosed with mild cognitive impairment may be eligible to participate in this trial. The goal of the study is to assess whether aducanumab, a drug that targets brain amyloid, can reduce brain amyloid levels and slow memory loss associated with amyloid build up. Participants will be randomized to receive active drug or placebo (inactive substance) via monthly infusions. The study lasts approximately 2 years, which includes an 8-week screening period and 4.5 month follow up period once the investigational drug/placebo phase is completed. To learn more, please call (310) 794-6191 or visit www.eastonad.ucla.edu.
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study:
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) Study is a clinical study for older individuals ages 65-85 who have normal thinking and memory function but who may be at risk for developing Alzheimer's disease (AD) memory loss sometime in the future. This study is sponsored by the National Institute on Aging, Eli Lilly, and the Alzheimer’s Therapeutic Research Institute. The purpose of the A4 study is to test whether a new investigational treatment can slow the memory loss associated with Alzheimer’s disease by decreasing amyloid levels in the brain. The A4 Study lasts for three years, and participants will be assigned at random to receive either the investigational drug or a placebo (inactive substance) via monthly infusions and will be regularly monitored over that period.
You may be eligible to join the A4 Study if you:
If you are interested in participating, please call (310) 794-6191 or visit www.eastonad.ucla.edu.
The CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants with Prodromal to Mild Alzheimer’s Disease (AD):
The CREAD study is a Phase III clinical trial sponsored by Genentech/F. Hoffman-La Roche of the investigational drug, crenezumab, which is an anti-amyloid antibody. The goal of the study is to test whether monthly infusions of crenezumab, will slow down disease progression and memory loss by reducing brain amyloid levels. Participants will have a 50% chance of receiving active study drug versus placebo (an inactive substance). The study lasts approximately 2 years, with 26 infusion visits and the possibility of an open label extension upon completion. Individuals ages 50-85 with a diagnosis of mild cognitive impairment (prodromal Alzheimer’s disease) and mild dementia due to Alzheimer’s disease may be eligible to participate. To learn more, please call (310) 794-6191 or visit www.eastonad.ucla.edu.
Curcumin and Yoga Therapy for Those at Risk for Alzheimer’s Disease: